Baxter Q1 revenue $3.65B (-2%); adjusted EPS $0.59 beats guidance

BAXTER INTERNATIONAL INC

2023-Q1 EPS reported $0.09 revenue$3,649,000,000

Q1 revenue $3.65B, -2% reported, +2% constant currency, exceeding prior guidance.
GAAP EPS $0.09; adjusted EPS $0.59, down 37% YoY but above guidance.
Full-year 2023 guidance: GAAP EPS $1.16-$1.31; adjusted $2.85-$3.00; sales growth 1-2% reported.
Q2 guidance: sales growth 1-2% reported; adjusted EPS $0.59-$0.61.
Kidney Care spinoff expected by July 2024 or earlier; new operating model into 4 segments underway.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BAXTER INTERNATIONAL INC reported first quarter of 2023 results: revenue $3.65 billion, net income $44 million, EPS $0.09 per diluted share. Guidance initiated.

Period: first quarter of 2023
Revenue: $3.65 billion
Net income: $44 million
EPS: $0.09 per diluted share
Guidance: initiated
Result: reported results

Exact text from the filing

First-quarter revenue of $3.65 billion decreased 2% on a reported basis and increased 2% on a constant currency basis 1 • First-quarter U.S. GAAP earnings per share (EPS) totaled $0.09; Adjusted EPS totaled $0.59

View on SEC.gov

Browse all earnings releases →

BAXTER INTERNATIONAL INC filing history →

Source: SEC EDGAR

accession 0001628280-23-013356

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.